Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

236 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer.
Gregorc V, Ceresoli GL, Floriani I, Spreafico A, Bencardino KB, Ludovini V, Pistola L, Mihaylova Z, Tofanetti FR, Ferraldeschi M, Torri V, Cappuzzo F, Crinò L, Tonato M, Villa E. Gregorc V, et al. Among authors: spreafico a. Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6006-12. doi: 10.1158/1078-0432.CCR-03-0770. Clin Cancer Res. 2004. PMID: 15447984
Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
Cappuzzo F, Magrini E, Ceresoli GL, Bartolini S, Rossi E, Ludovini V, Gregorc V, Ligorio C, Cancellieri A, Damiani S, Spreafico A, Paties CT, Lombardo L, Calandri C, Bellezza G, Tonato M, Crinò L. Cappuzzo F, et al. Among authors: spreafico a. J Natl Cancer Inst. 2004 Aug 4;96(15):1133-41. doi: 10.1093/jnci/djh217. J Natl Cancer Inst. 2004. PMID: 15292385 Clinical Trial.
Pharmacogenetics of ABCG2 and adverse reactions to gefitinib.
Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll RG, Verweij J, Ludovini V, Villa E, Hidalgo M, Sparreboom A, Baker SD. Cusatis G, et al. Among authors: spreafico a. J Natl Cancer Inst. 2006 Dec 6;98(23):1739-42. doi: 10.1093/jnci/djj469. J Natl Cancer Inst. 2006. PMID: 17148776
Serum level changes of matrix metalloproteinases 2 and 9, vascular endothelial growth factor and epidermal growth factor receptor during platinum-based chemotherapy in advanced non-small cell lung cancer patients.
Mihaylova Zh, Ludovini V, Gregorg V, Floriani I, Pistola L, Toffaneti F, Ferraldeschi M, Spreafico A, Ceresoli GL, Bellet M, Darwish S, Tonato M, Raynov J. Mihaylova Zh, et al. Among authors: spreafico a. J BUON. 2007 Jan-Mar;12(1):105-11. J BUON. 2007. PMID: 17436410 Clinical Trial.
Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.
Taguchi F, Solomon B, Gregorc V, Roder H, Gray R, Kasahara K, Nishio M, Brahmer J, Spreafico A, Ludovini V, Massion PP, Dziadziuszko R, Schiller J, Grigorieva J, Tsypin M, Hunsucker SW, Caprioli R, Duncan MW, Hirsch FR, Bunn PA Jr, Carbone DP. Taguchi F, et al. Among authors: spreafico a. J Natl Cancer Inst. 2007 Jun 6;99(11):838-46. doi: 10.1093/jnci/djk195. J Natl Cancer Inst. 2007. PMID: 17551144
Endothelial growth factor receptor inhibition after radiotherapy.
Giovannini M, Gregorc V, Viganò MG, Spreafico A, Ghio D, Dell'Oca I, Bolognesi A, Villa E. Giovannini M, et al. Among authors: spreafico a. J Thorac Oncol. 2007 Jul;2(7):662. doi: 10.1097/JTO.0b013e318074de48. J Thorac Oncol. 2007. PMID: 17607125 Free article. No abstract available.
Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2.
Hesketh PJ, Chansky K, Wozniak AJ, Hirsch FR, Spreafico A, Moon J, Mack PC, Marchello BT, Franklin WA, Crowley JJ, Gandara DR. Hesketh PJ, et al. Among authors: spreafico a. J Thorac Oncol. 2008 Sep;3(9):1026-31. doi: 10.1097/JTO.0b013e318183aa1f. J Thorac Oncol. 2008. PMID: 18758306 Free PMC article. Clinical Trial.
236 results